Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trial watch: TLR3 agonists in cancer therapy
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 220

Showing 26-50 of 220 citing articles:

Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity
Kathleen M. McAndrews, Sara P.Y., Valerie S. LeBleu, et al.
Journal of Biological Chemistry (2021) Vol. 296, pp. 100523-100523
Open Access | Times Cited: 58
The Evolution of STING Signaling and Its Involvement in Cancer
Nimi Vashi, Samuel F. Bakhoum
Trends in Biochemical Sciences (2021) Vol. 46, Iss. 6, pp. 446-460
Open Access | Times Cited: 57
Beyond Good and Evil: Molecular Mechanisms of Type I and III IFN Functions
Jack W. Dowling, Adriana Forero
The Journal of Immunology (2022) Vol. 208, Iss. 2, pp. 247-256
Open Access | Times Cited: 42
Colorectal cancer vaccines: The current scenario and future prospects
Wenqing Jia, Tao Zhang, Haiyan Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 36
STING agonism turns human T cells into interferon‐producing cells but impedes their functionality
Niklas Kühl, Andreas Linder, Nora Philipp, et al.
EMBO Reports (2023) Vol. 24, Iss. 3
Open Access | Times Cited: 35
Vaccines as treatments for prostate cancer
Ichwaku Rastogi, Anusha Muralidhar, Douglas G. McNeel
Nature Reviews Urology (2023) Vol. 20, Iss. 9, pp. 544-559
Open Access | Times Cited: 33
Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect
Furong Cheng, Ting Su, Shurong Zhou, et al.
Science Advances (2023) Vol. 9, Iss. 28
Open Access | Times Cited: 33
Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer
Chih‐Hung Chung, Chun‐Yu Lin, Chih‐Yu Chen, et al.
Advanced Science (2023) Vol. 10, Iss. 15
Open Access | Times Cited: 32
Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives
Cuiqing Huang, Ni Shao, Yanyu Huang, et al.
Materials Today Bio (2023) Vol. 23, pp. 100839-100839
Open Access | Times Cited: 30
Trial watch: Toll-like receptor ligands in cancer therapy
Julie Le Naour, Guido Kroemer
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 25
Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy
Larsen Vornholz, Sophie E. Isay, Zsuzsanna Kurgyis, et al.
Science Advances (2023) Vol. 9, Iss. 11
Open Access | Times Cited: 24
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
Kyle Concannon, Benjamin B. Morris, Carl M. Gay, et al.
Molecular Cell (2023) Vol. 83, Iss. 5, pp. 660-680
Open Access | Times Cited: 23
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
Inês Mota, Enrico Patrucco, Cristina Mastini, et al.
Nature Cancer (2023) Vol. 4, Iss. 7, pp. 1016-1035
Closed Access | Times Cited: 23
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Giulia Petroni, Serena Pillozzi, Lorenzo Antonuzzo
Cancer Research (2024) Vol. 84, Iss. 8, pp. 1199-1209
Open Access | Times Cited: 9
Engineering cGAS-agonistic oligonucleotides as therapeutics for cancer immunotherapy
Shurong Zhou, Ting Su, Furong Cheng, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 1, pp. 102126-102126
Open Access | Times Cited: 8
Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy
Muyang Yang, Jie Zhou, Liseng Lu, et al.
Exploration (2024) Vol. 4, Iss. 6
Open Access | Times Cited: 7
Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer
Alessandro Alaimo, Sacha Genovesi, Nicole Annesi, et al.
The EMBO Journal (2024) Vol. 43, Iss. 5, pp. 780-805
Open Access | Times Cited: 6
The interaction of innate immune and adaptive immune system
Ruyuan Wang, Caini Lan, Kamel Benlagha, et al.
MedComm (2024) Vol. 5, Iss. 10
Open Access | Times Cited: 6
De novo design of protein minibinder agonists of TLR3
Chloe S. Adams, Hyojin Kim, Abigail E. Burtner, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
An anoikis-related signature predicts prognosis and immunotherapy response in gastrointestinal cancers
Ruyi Liu, Yuchen Liu, Wei‐Cheng Huang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
cGAS–STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells
Manuel Adrian Suter, Nikki Yi Jie Tan, Chung Hwee Thiam, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 51
Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides
Ilio Vitale, Takahiro Yamazaki, Erik Wennerberg, et al.
Trends in cancer (2021) Vol. 7, Iss. 6, pp. 557-572
Open Access | Times Cited: 50
Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects
M. Brittany Johnson, Morgan Chandler, Kirill A. Afonin
Advanced Drug Delivery Reviews (2021) Vol. 173, pp. 427-438
Open Access | Times Cited: 49
In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma
Isabella Lurje, Wiebke Werner, Raphael Mohr, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 41
CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma
Cerise Yuen‐Ki Chan, David Kung‐Chun Chiu, Vincent Wai‐Hin Yuen, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 32
Open Access | Times Cited: 35

Scroll to top